Biotechnology Financing Activity

A clinical-stage biotech company is a peculiar kind of issuer: it has no product, no revenue, and a burn rate set by the price of evidence. Its financing calendar is therefore a map of its science — each raise sized to reach the next data readout, because the readout is what reprices the company. How that money arrives, and through which instrument, says a great deal about market conditions.

In 2025, conditions were harsh and the instruments showed it. Public-market funding for biotech hit a trough in May at roughly $1.1 billion for the month, against an aggregate sector burn Jefferies put near $4.5 billion a month. Issuers responded by going private in public: the large majority of follow-on equity raises were executed as wall-crossed offerings, PIPEs or registered directs — negotiated quietly with specialist funds rather than launched into the open market.

DealForma's tallies capture the mix: in the fourth quarter of 2025, biopharma companies completed 52 follow-ons for $11.5 billion, 49 PIPEs for $4.8 billion, and just seven IPOs for $1.0 billion.

The terms carried the market's skepticism. Wilson Sonsini's 2025 data shows life-sciences PIPEs pricing at average discounts around 5 percent with warrant coverage in nearly half of transactions, and tranched structures — second closings triggered by clinical milestones — became a standard way for investors to pay for proof in installments. A parallel channel boomed: royalty financing, in which companies sell a slice of future drug sales instead of equity, reached roughly $10 billion of announced transactions in 2025, including Royalty Pharma's up-to-$1.25 billion synthetic royalty on Revolution Medicines' pancreatic-cancer candidate.

Then the window reopened. Thirteen biopharma IPOs raised about $5.0 billion in the first half of 2026 — more than any full year from 2022 through 2025, per J.P. Morgan's deal tracking — and quarterly follow-on volume roughly quadrupled from a year earlier. The lesson for issuers is the one the sector relearns every cycle: the instruments rotate with sentiment, but evidence is the only currency that converts across all of them.

Data notes: Data providers use different universes (DealForma tracks therapeutics and platform companies; J.P. Morgan's biopharma scope is broader than some biotech-only tallies) — figures from different trackers are not additive. Royalty totals are announced transaction values, which can include contingent tranches.